PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI)

Historical Holders from Q1 2014 to Q3 2025

Symbol
PBYI on Nasdaq
CUSIP
74587V107
Type / Class
Equity / Common Stock
Shares outstanding
49.6M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
34.4M
Holdings value
$182M
% of all portfolios
0%
Grand Portfolio weight change
+0%
Number of holders
128
Number of buys
62
Number of sells
-49
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ACORN BIOVENTURES, L.P. 8% +18.6% $11.5M $1.92M 3.94M +20.1% Anders Hove Dec 31, 2024
BlackRock, Inc. 5.6% $8.09M 2.78M BlackRock, Inc. Mar 31, 2025
MILLENNIUM MANAGEMENT LLC 3.9% $5.51M 1.89M Millennium Management LLC Dec 31, 2024

Institutional Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 34.4M $182M +$11.6M $5.31 128
2025 Q2 32.8M $112M +$8.6M $3.43 121
2025 Q1 30.4M $90M +$2.95M $2.96 116
2024 Q4 29.4M $89.6M -$7.8M $3.05 111
2024 Q3 29.7M $75.9M -$5.78M $2.55 101
2024 Q2 31M $101M -$1.24M $3.26 98
2024 Q1 29.7M $157M +$15.8M $5.30 95
2023 Q4 57.2K $248K +$141K $4.33 1
2023 Q3 25.7M $67.6M -$2.43M $2.63 67
2023 Q2 26.6M $93.8M -$4.38M $3.53 67
2023 Q1 27.9M $86.1M -$528K $3.09 77
2022 Q4 27.5M $116M -$150K $4.23 84
2022 Q3 27.6M $65.5M -$1.68M $2.37 70
2022 Q2 27.6M $78.6M -$4.2M $2.85 74
2022 Q1 29.4M $84.7M -$205K $2.88 93
2021 Q4 30.2M $91.8M -$38.9M $3.04 94
2021 Q3 31.7M $222M -$28.8M $7.01 112
2021 Q2 34.1M $313M -$20.3M $9.18 116
2021 Q1 36.5M $355M +$11.7M $9.72 115
2020 Q4 32.1M $329M -$10.2M $10.26 118
2020 Q3 38.6M $390M +$12.7M $10.09 125
2020 Q2 32.1M $335M -$7.02M $10.43 121
2020 Q1 31.7M $267M +$39.2M $8.44 116
2019 Q4 31.1M $272M -$65.2M $8.75 127
2019 Q3 33.4M $359M +$12.5M $10.77 134
2019 Q2 31.8M $404M -$100M $12.71 128
2019 Q1 33.2M $1.29B +$6.94M $38.79 152
2018 Q4 34.9M $711M -$233M $20.35 133
2018 Q3 35.6M $1.63B +$1.14M $45.85 154
2018 Q2 35.5M $2.1B +$48.1M $59.15 167
2018 Q1 35.6M $2.42B -$81.3M $68.05 166
2017 Q4 36.2M $3.57B -$112M $98.85 192
2017 Q3 36.7M $4.39B +$170M $119.75 169
2017 Q2 35.5M $3.1B +$54.1M $87.40 152
2017 Q1 37.9M $1.41B +$190M $37.20 134
2016 Q4 34.9M $1.07B +$72.9M $30.70 127
2016 Q3 30M $2.01B +$5.53M $67.05 145
2016 Q2 31.6M $943M +$45.4M $29.79 105
2016 Q1 30.3M $890M -$118M $29.37 111
2015 Q4 32.2M $2.52B +$179M $78.40 130
2015 Q3 30.1M $2.27B -$28.2M $75.36 157
2015 Q2 30.1M $3.52B -$43.6M $116.75 194
2015 Q1 29.1M $6.87B +$478M $236.11 196
2014 Q4 27.1M $5.14B +$67.8M $189.27 182
2014 Q3 26.7M $6.37B +$471M $238.57 185
2014 Q2 25.4M $1.67B -$31.6M $66.00 131
2014 Q1 25.1M $2.61B +$106M $104.14 129